Nasacort AQ and Pregnancy
In animal studies on Nasacort AQ and pregnancy, the drug increased the risk of birth defects when it was given to pregnant rabbits, rats, and monkeys. Although it has not been studied in humans, the FDA gave it a pregnancy Category C rating. Due to the potential risks, notify your healthcare provider immediately if you are taking Nasacort AQ and pregnancy occurs.
Nasacort® AQ (triamcinolone nasal spray) is a prescription medication approved to treat nasal allergies in adults and children as young as two years old. It belongs to a group of medications known as corticosteroids. As with many other corticosteroids, animal studies have shown that Nasacort AQ can increase the risk of birth defects.
The U.S. Food and Drug Administration (FDA) uses a category system to classify the possible risks to a fetus when a specific medicine is taken during pregnancy. Pregnancy Category C is given to medicines that have not been studied in pregnant humans but that do appear to cause harm to the fetus in animal studies. Also, medicines that have not been studied in any pregnant women or animals are automatically given a pregnancy Category C rating.
Nasacort AQ was assigned a pregnancy Category C classification because of problems in animal studies. When given to rats, rabbits, and monkeys, triamcinolone (the active ingredient in Nasacort AQ) increased the risk of birth defects, including cleft palate and hydrocephalus (fluid accumulation in the brain). The drug has not been adequately studied in pregnant women, so it is not known whether similar problems would occur in humans.
It is important to note that animals do not always respond to medicines the same way that humans do. Therefore, a pregnancy Category C medicine may be given to a pregnant woman if her healthcare provider believes that the benefits to the woman outweigh any possible risks to the unborn child.